Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
21 Results for "
v-Abl
" in MedChemExpress (MCE) Product Catalog:
Products (21)
21 Results for "v-Abl" in MCE Product Catalog:
135
135 Cited Publications
Synonyms: STI571; CGP-57148B
Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .
1
1 Cited Publications
Synonyms: STI571-d8; CGP-57148B-d8
Cat. No.: HY-W062835
CAS No.: 234772-64-6
CGP77675 is an orally active and potent inhibitor of Src family kinases. CGP77675 inhibits phosphorylation of peptide substrates and autophosphorylation of purified Src (IC50s of 5-20 and 40 nM, respectively), and also inhibits Src, EGFR, KDR, v-Abl, and Lck with IC50s of 5-20, 40, 20, 150, 1000, 310, and 290 nM, respectively. Anticancer activity .
Synonyms: STI571 d4; CGP-57148B d4
Cat. No.: HY-15463R
CAS No.: 152459-95-5
Synonyms: STI571 (Standard); CGP-57148B (Standard)
Imatinib (Standard) is the analytical standard of Imatinib. This product is intended for research and analytical applications. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .
Cat. No.: HY-15463S3
Synonyms: STI571-13C,d3; CGP-57148B-13C,d3
Cat. No.: HY-N14635
CAS No.: 162797-33-3
Category:
Target:
Cat. No.: HY-N14637
CAS No.: 92439-42-4
Category:
Target:
Cat. No.: HY-W062835A
CGP77675 hydrate is an orally active and potent inhibitor of Src family kinases. CGP77675 hydrate inhibits phosphorylation of peptide substrates and autophosphorylation of purified Src (IC50s of 5-20 and 40 nM, respectively),and also inhibits Src, EGFR, KDR, v-Abl, and Lck with IC50s of 0.02, 0.15, 1.0, 0.31, and 0.29 μM, respectively. Anticancer activity .
Synonyms: STI571-d3 hydrochloride; CGP-57148B-d3 hydrochloride
Target:
Research Areas:
Imatinib Impurity E is the impurity of Imatinib. Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .
Cat. No.: HY-131275R
CAS No.: 1365802-18-1
Target:
Research Areas:
Imatinib Impurity E (Standard) is the analytical standard of Imatinib Impurity E (HY-131275). This product is intended for research and analytical applications. Imatinib Impurity E is the impurity of Imatinib. Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .
Cat. No.: HY-RS00102
Target:
Research Areas:
ABL1 Human Pre-designed siRNA Set A contains three designed siRNAs for ABL1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-P706237
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: Abl1; BCR/Abl1 E1a2 Fusion Protein; Prev. Abl; Bcr/C-Abl Oncogene Protein; JTK7; Chimeric BCR::Abl1 Protein; P150; BCR::Abl1 Fusion Protein; C-Abl; BCR/Abl E8a2 Fusion; V-Abl Abelson Murine Leukemia Viral Oncogene Homolog 1; BCR/Abl1 Fusion; C-Abl Oncogene 1, Receptor Tyrosine Kinase; BCR-Abl1 P190; Abelson Tyrosine-Protein Kinase 1; Abl1 Protein; Tyrosine-Protein Kinase Abl1; BCR-Abl; Proto-Oncogene C-Abl; Bcr/Abl; Abelson Murine Leukemia Viral Oncogene Homolog 1; CHDSKM; Abl Protooncogene 1 Nonreceptor Tyrosine Kinase; C-Abl1; C-Abl Oncogene 1, Non-Receptor Tyrosine Kinase; V-Abl; Proto-Oncogene Tyrosine-Protein Kinase Abl1; C-Abl; Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase; BCR/Abl1 Fusion Protein E3a1
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-P71685
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: Abl1; BCR/Abl1 E1a2 Fusion Protein; Prev. Abl; Bcr/C-Abl Oncogene Protein; JTK7; Chimeric BCR::Abl1 Protein; P150; BCR::Abl1 Fusion Protein; C-Abl; BCR/Abl E8a2 Fusion; V-Abl Abelson Murine Leukemia Viral Oncogene Homolog 1; BCR/Abl1 Fusion; C-Abl Oncogen
Species:
Human
Source:
E. coli
Cat. No.: HY-P77308
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: Abl1; BCR/Abl1 E1a2 Fusion Protein; Prev. Abl; Bcr/C-Abl Oncogene Protein; JTK7; Chimeric BCR::Abl1 Protein; P150; BCR::Abl1 Fusion Protein; C-Abl; BCR/Abl E8a2 Fusion; V-Abl Abelson Murine Leukemia Viral Oncogene Homolog 1; BCR/Abl1 Fusion; C-Abl Oncogen
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-P702716
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: Abl1; BCR/Abl1 E1a2 Fusion Protein; Prev. Abl; Bcr/C-Abl Oncogene Protein; JTK7; Chimeric BCR::Abl1 Protein; P150; BCR::Abl1 Fusion Protein; C-Abl; BCR/Abl E8a2 Fusion; V-Abl Abelson Murine Leukemia Viral Oncogene Homolog 1; BCR/Abl1 Fusion; C-Abl Oncogen
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-P705723
Purity: ≥ 80%, as determined by reducing SDS-PAGE.
Synonyms: Abl1; BCR/Abl1 E1a2 Fusion Protein; Prev. Abl; Bcr/C-Abl Oncogene Protein; JTK7; Chimeric BCR::Abl1 Protein; P150; BCR::Abl1 Fusion Protein; C-Abl; BCR/Abl E8a2 Fusion; V-Abl Abelson Murine Leukemia Viral Oncogene Homolog 1; BCR/Abl1 Fusion; C-Abl Oncogen
Species:
Human
Source:
sf9 insect cells
Cat. No.: HY-P705725
Purity: ≥ 85%, as determined by reducing SDS-PAGE.
Synonyms: Abl1; BCR/Abl1 E1a2 Fusion Protein; Prev. Abl; Bcr/C-Abl Oncogene Protein; JTK7; Chimeric BCR::Abl1 Protein; P150; BCR::Abl1 Fusion Protein; C-Abl; BCR/Abl E8a2 Fusion; V-Abl Abelson Murine Leukemia Viral Oncogene Homolog 1; BCR/Abl1 Fusion; C-Abl Oncogen
Species:
Human
Source:
sf9 insect cells
Cat. No.: HY-P705724
Purity: ≥ 80%, as determined by reducing SDS-PAGE.
Synonyms: Abl1; BCR/Abl1 E1a2 Fusion Protein; Prev. Abl; Bcr/C-Abl Oncogene Protein; JTK7; Chimeric BCR::Abl1 Protein; P150; BCR::Abl1 Fusion Protein; C-Abl; BCR/Abl E8a2 Fusion; V-Abl Abelson Murine Leukemia Viral Oncogene Homolog 1; BCR/Abl1 Fusion; C-Abl Oncogen
Species:
Human
Source:
sf9 insect cells
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
